Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Multi-center, Randomized, Double Blind, Placebo-controlled, Crossover Study to Evaluate Multiple Doses of ALLN-177 in Recurrent Calcium Oxalate Kidney Stone Formers With Hyperoxaluria

NCT02503345 is registered in ClinicalTrials.gov with Allena Pharmaceuticals as lead sponsor.

NCT NCT02503345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02503345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Multi-center, Randomized, Double Blind, Placebo-controlled, Crossover Study to Evaluate Multiple Doses of ALLN-177 in Recurrent Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
Lead sponsor
Allena Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2015
Completion date
January 31, 2017
Enrollment
32 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

dietary hyperoxaluria, hyperoxaluria, kidney stones, nephrolithiasis, secondary hyperoxaluria